美国带状疱疹疫苗市场规模、份额和趋势分析报告：按产品、疫苗类型、最终用途和细分市场预测，2025 年至 2033 年

美国带状疱疹疫苗市场规模与趋势：

预计到 2024 年，美国带状疱疹疫苗市场规模将达到 34.1 亿美元，2025 年至 2033 年的复合年增长率为 10.17%。

市场成长的关键驱动因素包括老年人口的不断增长、人们对带状疱疹相关併发症认识的不断提高以及重组疫苗技术的广泛应用。在预防保健领域，带状疱疹疫苗对于减轻50岁及以上成年人（尤其是免疫系统较弱的人群）的疾病负担至关重要。双剂型佐剂疫苗的推出提高了疫苗的长期疗效和接种率。此外，基于mRNA的带状疱疹疫苗的持续研发以及疫苗接种方案的改进，将继续支持疫苗的接种和市场扩张。

老年人对长期免疫保护的需求日益增长，促使疫苗设计显着改进，重点在于提高免疫反应和安全性。 Shingrix 等基因定序疫苗已展现出卓越的临床效果，并广泛推荐用于美国成年人口。包括基于 mRNA 的製剂在内的新型候选疫苗正在开发中，旨在提供更便捷的给药方式、更广泛的免疫保护和更高效的生产流程。这些技术创新预计将在未来几年增强市场，尤其是在预防性医疗保健需求日益增长的情况下。

支持性的医疗基础设施和公共卫生政策也在塑造美国带状疱疹疫苗的格局。联邦倡议、成人疫苗宣传活动以及医疗保险对带状疱疹疫苗的覆盖，改善了老年人的接种途径，并减少了经济障碍。随着癌症、器官移植和慢性疾病导致免疫力缺乏人群的增加，带状疱疹疫苗接种已成为临床指南的强制性组成部分。为此，医疗保健系统正在扩大推广，并将成人疫苗接种纳入常规就诊，以符合更广泛的公共卫生目标。

持续的研发和产品创新投入进一步提高了疫苗的可及性。公私合作和资金投资正在加速临床试验，并促进佐剂系统和mRNA平台等先进技术的应用。此外，真实世界临床试验提供了长期有效性的证据，支持了疫苗的可信度和广泛应用。虽然目前美国市场由定序主导，但全球对带状疱疹疫苗日益增长的兴趣体现在其他地区的新产品核可上，例如SKYZoster，该疫苗于2023年在马来西亚核准。这些进展预示着未来市场扩张和竞争的潜力。

由于成人疫苗接种日益受到重视、疾病负担不断增加以及技术进步，美国带状疱疹疫苗市场预计将保持强劲成长。该行业正致力于改善免疫反应、降低给药复杂性，并透过私人和公共卫生管道扩大推广。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国带状疱疹疫苗市场变数、趋势和范围

• 市场体系展望
  • 母市场展望
  • 相关/附随市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 美国带状疱疹疫苗市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析

第四章美国带状疱疹疫苗市场：产品评估与趋势分析

• 2024年及2033年的产品市场占有率
• 细分仪表板
• 美国带状疱疹疫苗市场：产品展望
• 2021年至2033年市场规模、预测与趋势分析
  • 定序
  • 佐斯塔瓦克斯
  • 天空之星

第五章美国带状疱疹疫苗市场：按疫苗类型进行的估计和趋势分析

• 2024 年和 2033 年疫苗类型市场占有率
• 细分仪表板
• 美国带状疱疹疫苗市场：疫苗类型展望
• 2021年至2033年市场规模、预测与趋势分析
  • 重组疫苗
  • 减毒活疫苗

第六章美国带状疱疹疫苗市场：最终用途估计和趋势分析

• 2024年及2033年最终用途市场占有率
• 细分仪表板
• 美国带状疱疹疫苗市场：最终用途展望
• 2021年至2033年市场规模、预测与趋势分析
  • 私人医疗机构
  • 政府医疗机构

第七章 竞争态势

• 主要市场参与企业的近期趋势和影响分析
• 公司/竞争对手分类
• 供应商格局
  • 主要经销商和通路合作伙伴名单
  • Key customers
  • Key company market share analysis, 2024
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Merck &Co., Inc.
  • CanSinoBIO
  • Vaccitech
  • Green Cross Corp
  • Geneone Life Science
  • SK Bioscience

U.S. Shingles Vaccine Market Size & Trends:

The U.S. Shingles Vaccine market size was valued at USD 3.41 billion in 2024 and is projected to register a CAGR of 10.17% during 2025 - 2033. Growth in the market is primarily driven by the expanding elderly population, increased awareness of shingles-related complications, and the broader adoption of recombinant vaccine technologies. In preventive healthcare, shingles vaccines are crucial for reducing disease burden among adults aged 50 and above, particularly those with compromised immune function. The introduction of two-dose, adjuvanted formulations has improved long-term efficacy and coverage. In addition, ongoing R&D efforts around mRNA-based shingles vaccines and improved immunization schedules continue to support uptake and market expansion.

The rising need for long-lasting protection in older adults has led to notable improvements in vaccine design, focusing on enhanced immune response and safety. Recombinant vaccines such as Shingrix have shown strong performance in clinical settings. They are widely recommended across the U.S. adult population. Newer vaccine candidates, including mRNA-based formulations, are being developed to offer simpler dosing, broader immune protection, and more efficient production timelines. These innovations are expected to strengthen the market over the coming years, especially as demand for preventive care grows.

Supportive healthcare infrastructure and public health policies also shape the U.S. shingles vaccine landscape. Federal initiatives, adult immunization campaigns, and Medicare coverage for shingles vaccination have improved access and reduced financial barriers for older adults. As the number of immunocompromised individuals rises due to cancer, organ transplants, and chronic conditions, shingles vaccination has become an essential part of clinical guidelines. In response, healthcare systems are expanding outreach, integrating adult vaccines into regular care visits, and aligning with broader public health goals.

Continued investment in R&D and product innovation is further enhancing vaccine availability. Public-private collaborations and funding support are helping accelerate clinical trials and promote the use of advanced technologies like adjuvant systems and mRNA platforms. In addition, real-world studies generate evidence of long-term efficacy, helping drive vaccine confidence and adoption. While Shingrix dominates the current U.S. market, growing global interest in shingles vaccines is reflected in new product approvals elsewhere, such as SKYZoster's approval in Malaysia in 2023. Such developments signal potential for future market expansion and competition.

The growing emphasis on adult vaccination, rising disease burden, and technological progress are expected to sustain strong growth in the U.S. Shingles Vaccine Market. The industry focuses on improving immune response, reducing dosing complexity, and expanding outreach through private and public health channels.

U.S. Shingles Vaccine Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. Shingles Vaccine market on the product,vaccine type, and end use:

• Product Outlook (Revenue in USD Million, 2021 - 2033)
  • Shingrix
  • Zostavax
  • SKYZoster
• Vaccine Type Outlook (Revenue in USD Million, 2021 - 2033)
  • Recombinant Vaccine
  • Live Attenuated Vaccine
• End Use Outlook (Revenue in USD Million, 2021 - 2033)
  • Private Healthcare Settings
  • Government Healthcare Settings

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Vaccine type
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in U.S.
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Vaccine type outlook
  • 2.2.3. End Use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Shingles Vaccine market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Aging Population & Rising Shingles Incidence
    • 3.2.1.2. Government Programs & Outreach Initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Vaccine Cost & Financial Barriers
    • 3.2.2.2. Vaccine Hesitancy & Logistical Hurdles
• 3.3. U.S. shingles vaccine market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Shingles Vaccine Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. U.S. Shingles Vaccine Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Shingrix
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Zostavax
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. SKYZoster
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Shingles Vaccine Market: Vaccine type Estimates & Trend Analysis

• 5.1. Vaccine type Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. U.S. Shingles Vaccine Market by Vaccine type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Recombinant Vaccine
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Live Attenuated Vaccine
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Shingles Vaccine Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. U.S. Shingles Vaccine Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Private Healthcare Settings
    • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 6.4.2. Government Healthcare Settings
    • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. GlaxoSmithKline plc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Pfizer Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Merck & Co., Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. CanSinoBIO
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Vaccitech
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Green Cross Corp
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Geneone Life Science
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. SK Bioscience
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. Shingles Vaccine Market, by Product, 2021 - 2033 (USD Million)
• Table 3 U.S. Shingles Vaccine Market, by Vaccine type, 2021 - 2033 (USD Million)
• Table 4 U.S. Shingles Vaccine Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in U.S.
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. Shingles Vaccine Market: market outlook
• Fig. 10 U.S. Shingles Vaccine competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. Shingles Vaccine Market driver impact
• Fig. 16 U.S. Shingles Vaccine Market restraint impact
• Fig. 17 U.S. Shingles Vaccine Market strategic initiatives analysis
• Fig. 18 U.S. Shingles Vaccine Market: Product movement analysis
• Fig. 19 U.S. Shingles Vaccine Market: Product outlook and key takeaways
• Fig. 20 Shingrix market estimates and forecast, 2021 - 2033
• Fig. 21 Zostavax market estimates and forecast, 2021 - 2033
• Fig. 22 SKYZoster market estimates and forecast, 2021 - 2033
• Fig. 23 U.S. Shingles Vaccine Market: Vaccine type movement Analysis
• Fig. 24 U.S. Shingles Vaccine Market: Vaccine type outlook and key takeaways
• Fig. 25 Recombinant Vaccine market estimates and forecasts, 2021 - 2033
• Fig. 26 Live Attenuated Vaccine market estimates and forecasts,2021 - 2033
• Fig. 27 U.S. Shingles Vaccine Market: End Use movement analysis
• Fig. 28 U.S. Shingles Vaccine Market: End Use outlook and key takeaways
• Fig. 29 Private Healthcare Settings market estimates and forecasts, 2021 - 2033
• Fig. 30 Government Healthcare Settings market estimates and forecasts,2021 - 2033
• Fig. 31 U.S. Shingles Vaccine Market share and leading players
• Fig. 32 U.S. market share and leading players
• Fig. 33 U.S. SWOT
• Fig. 34 U.S. market estimates and forecasts, 2021 - 2033
• Fig. 35 Market share of key market players- U.S. Shingles Vaccine Market